Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EVO
SellEvotec SE · Healthcare · Germany · $679M · Avg Vol: $112K/d
COMPANY DESCRIPTION
Evotec SE is a leading drug discovery and development company providing high-quality research solutions and strategic alliances to pharmaceutical and biotechnology partners worldwide. The company's competitive advantage lies in its comprehensive portfolio of proprietary technology platforms, deep scientific expertise across multiple therapeutic areas, and a flexible business model spanning fee-for-service and co-ownership drug development. This positions Evotec as a critical innovation engine for the global life sciences industry.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 618.0M | 870.7M | 905.5M | 923.5M | 913.5M | 10.3% | 836.8M | 694.8M | 833.3M | -4.5% |
| EPS | 0.65 | -0.29 | -0.14 | -0.32 | -0.17 | — | -0.65 | — | — | — |
| Shares | 176.9M | 355.2M | 355.2M | 355.2M | 355.2M | +100.8% | 355.4M | — | — | — |
| Debt | 512.9M | 587.1M | 725.6M | 513.9M | 518.8M | 0.3% | 555.1M | — | — | — |
| Equity | 1.4B | 1.4B | 1.3B | 1.1B | 942.9M | -9.0% | — | — | — | — |
| Op CF | 126.6M | 238.5M | 42.2M | 21.1M | -10.6M | -45.0% | -134.2M | — | — | — |
| Inv CF | -242.8M | -478.3M | -15.4M | -82.5M | 198.8M | — | — | — | — | — |
| Fin CF | 393.0M | -67.4M | 83.4M | -187.0M | -43.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EVO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EVO | Evotec SE(you) | $679M | 23 | Sell |
| DMP.DE | Dermapharm Holding SE | $2.3B | 94 | Strong Buy |
| NNNN | Anbio Biotechnology | $337M | 19 | Strong Sell |
| FYB.DE | Formycon AG | $380M | 36 | Hold |
| IMTX | Immatics N.V. | $1.4B | 11 | Strong Sell |
| IFRX | InflaRx N.V. | $329M | 39 | Hold |
| QUCY | Quantum Cyber N.V. | $119M | 21 | Sell |
| GXI.DE | Gerresheimer AG | $1.1B | 56 | Hold |
| VRXA | Veraxa Biotech AG | $191M | 1 | Strong Sell |
| MRK.DE | Merck KGaA | $70.7B | 85 | Strong Buy |
Peer medians: ROE 7.2% · P/E 16.5x · Gross margin 45.7%